Dosing underway for Unity Biotech's UBX1325 in early-stage diabetic macular edema study
Unity Biotechnology ([[UBX]] +8.3%) has dosed the first patient in a Phase 1 study of UBX1325 in patients with diabetic macular edema ((DME)).The single-ascending dose, 15-subject study will evaluate the
Seekingalpha · 10/12 15:40
UNITY Biotechnology Announces First Patient Dosed In Phase 1 Study Of UBX1325 In Diabetic Macular Edema
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology ("UNITY") (NASDAQ:UBX), a
Benzinga · 10/12 12:01
Silicon Valley's most prominent VC firm had a banner week: $9 billion in IPO shares while helping TikTok negotiations
Venture capital firm Sequoia has long been the envy of its Silicon Valley peers, but has rarely had a week like this one. · 09/18 21:22
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
\- Corporate restructuring to extend cash runway through mid-2022 and key milestones -\- UBX1325 to enter clinical development in patients with diabetic macular edema -SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company
GlobeNewswire · 09/15 12:00
Unity is seizing control of IPO pricing from bankers, a rare move that could limit first-day pop
As Unity prepares for its stock market debut this week, CEO John Riccitiello will be making the decision on where the shares price, taking control from bankers · 09/14 20:23
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the following
GlobeNewswire · 09/04 13:00
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
New finance chief for Unity Biotechnology
Unity Biotechnology (UBX) has appointed Lynne Sullivan as chief financial officer, effective September 1, 2020. Ms. Sullivan most recently served as CFO for Compass Therapeutics.Shares up 1.3% premarket.Press release
Seekingalpha · 09/01 11:24
UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the appointment of Lynne Sullivan to the permanent role of chief financial
GlobeNewswire · 08/31 21:05
Unity Biotechnology (UBX) Jumps: Stock Rises 7.1%
Unity Biotechnology (UBX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks · 08/25 13:39
Wall Street Breakfast: The Week Ahead
Seeking Alpha - Article · 08/22 12:50
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Data, Sorrento To Buy R&D Partner, Kymera IPO
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 20)
Benzinga · 08/21 11:43
Unity Biotechnology Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Unity Biotechnology suffers setback for lead drug candidate UBX0101.ChromaDex reports positive Niagen news for heart failure.Vanda reports positive interim data from ODYSSEY study.
Seekingalpha · 08/20 17:05
SHIP, FORD, BE and LODE among midday movers
Gainers: MICT (MICT) +52%.RISE Education Cayman (REDU) +49%.Forward Industries (FORD) +29%.MOGU (MOGU) +28%.OneSmart International Education (ONE) +25%.Aduro Biotech (ADRO) +24%.Natural Gas Services (NGS) +19%.Bloom Energy (BE) +19%.Invacare (IVC) +15%.Tarena International (TEDU) +14%.Losers: Seanergy
Seekingalpha · 08/18 16:47
Healthcare - Top 5 Gainers / Losers
Gainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology
Seekingalpha · 08/18 15:02
Unity Shares Slump 66% As Lead Arthritis Drug Fails in Study
Unity's (UBX) lead pipeline candidate, UBX0101, fails to meet primary endpoint in a phase II study in patients with moderate-to-severe painful osteoarthritis of the knee.
Zacks · 08/18 14:21
The Daily Biotech Pulse: Poseida's Phase 1 Study Placed On Clinical Hold, Orphan Drug Designation For Krystal Biotech, Tiziana's Patent Award
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 12:21
Unity Biotechnology And Senescent Cell Therapy
Senescent cells secrete various inflammation signals and other molecules that actually seem to impair the function (and even the survival) of the cells around them.The compound's development has been halted, and Unity's stock took a dreadful beating Monday morning on the NASDAQ.I continue to think that combating aging is a very exciting area for therapeutic intervention, with potential effects on both overall health and lifespan.
Seekingalpha · 08/18 12:03
Morgan Stanley Downgrades Unity Biotechnology to Equal-Weight, Announces $5 Price Target
Morgan Stanley analyst Matthew Harrison downgrades Unity Biotechnology (NASDAQ:UBX) from Overweight to Equal-Weight and announces $5 price target.
Benzinga · 08/18 11:21
Citigroup Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $5
Citigroup analyst Yigal Nochomovitz downgrades Unity Biotechnology (NASDAQ:UBX) from Buy to Neutral and lowers the price target from $31 to $5.
Benzinga · 08/18 10:57
Webull provides a variety of real-time UBX stock news. You can receive the latest news about Unity Btech through multiple platforms. This information may help you make smarter investment decisions.
About UBX
Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.